Mount Sinai launches vaccine company for ‘inevitable’ future pandemics

New York City-based Mount Sinai Health System is launching CastleVax, its own vaccine company, to meet “future pandemic threats,” according to an Aug. 9 press release.

Advertisement

With CastleVax, the health system said it plans to evaluate its vaccine platform technology developed from Newcastle disease virus, which birds can contract but is harmless to people. The company is currently testing a potential COVID-19 nasal vaccine in an early trial and will embark on an omicron-targeted vaccine candidate, which other vaccine-makers are racing to distribute this fall. 

“COVID-19 is the first step for our platform development,” Matt Stober, CastleVax president and CEO, said in a statement. “We aim to engineer vaccines to fight a broad range of future respiratory pandemic threats that experts in the field foresee as inevitable.”

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.